Wanbury Receives USFDA Form 483 with Six Observations

Date: July 20, 2026

Regulatory Inspection Update

A routine current Good Manufacturing Practices (cGMP) inspection was conducted by the United States Food and Drug Administration (USFDA) at the company's facility located at Tanuku, West Godavari District, Andhra Pradesh. The inspection period was from July 13, 2026 to July 17, 2026.

At the conclusion of the inspection, the USFDA issued a Form 483 containing six observations. The company has committed to responding to these observations within the stipulated time frame set by the FDA.

The company will keep the stock exchanges informed of any further updates regarding this matter.

Other Sections

Not Specified: Financial Results, Dividend Declaration, KMP/Board/Auditor Changes, Board Meeting Outcomes, Auditor's Report, Disinvestment/Strategic Actions, Media Release/Investor Communication